Researchers from New Century Health and Neighborhood Health Plan of Rhode Island presented findings from their efforts to increase adoption of hypofractionation in breast cancer patients at the National Comprehensive Cancer Care Network conference, on March 31.
Clairity Inc. received FDA De Novo authorization for CLAIRITY BREAST, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram. With this authorization, Clairity is planning to launch among leading health systems through 2025—propelling a new era of precision medicine in breast cancer.
